© 2020 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2020 MJH Life Sciences™ and OncLive. All rights reserved.
November 24, 2020
Paul C. Boutros, PhD, MBA, discusses the utility of genetic testing in prostate cancer.
November 02, 2020
Ritu Salani, MD, MBA, discusses therapeutic advances in endometrial cancer.
Gottfried E. Konecny, MD, discusses potential strategies to overcome PARP resistance, future combinations with PARP inhibitors, and other unmet needs in ovarian cancer.
October 31, 2020
Ritu Salani, MD, MBA, discusses updates to PARP inhibition and FRα-targeting agents in ovarian cancer, the role of bevacizumab across all lines of ovarian cancer therapy, and immunotherapy highlights in cervical and endometrial cancer.
October 30, 2020
Mae Zakhour, MD, discusses the rise of PARP inhibitors as frontline maintenance therapy in advanced ovarian cancer and the key data that supported these regulatory decisions.
October 26, 2020
Paul C. Boutros, PhD, MBA, discusses processes that predict disease lethality in men with prostate cancer.